76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Harmony Biosciences Holdings Inc
Closed
SectorHealthcare
35.04 2.67
Overview
Share price change
24h
Min
33.4
Max
35.28
Income | -3.9M 46M |
|---|---|
Sales | -17M 185M |
P/E Sector Avg | 13.607 56.602 |
EPS | 0.779 |
Profit margin | 24.663 |
Employees | 268 |
EBITDA | -10M 56M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +54.45% upside |
Next Earnings | 5 Aug 2025 |
|---|
Market Cap | 307M 2B |
|---|---|
Previous open | 32.37 |
Previous close | 35.04 |
News Sentiment
By Acuity
7%
93%
1 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Harmony Biosciences Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Harmony Biosciences Holdings Inc Forecast
Price Target
By TipRanks
54.45% upside
12 Months Forecast
Average 51.57 USD 54.45%
High 70 USD
Low 31 USD
Based on 7 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.
Sentiment
By Acuity
1 / 382 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
